Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective St
In patients with extensive-stage SCLC and ECOG-PS 2-3, the addition of atezolizumab or durvalumab to platinum-doublet chemotherapies improved the ORR, resulting in a better prognosis. These findings suggest that chemoimmunotherapy may be a feasible treatment option beyond the ideal clinical trial populations, addressing an unmet clinical need.
Authors
- Maiko Sasaki‐Toda
- Nobuyuki Koyama
- Yoshiki Kuwabara
- Kosuke Sakai (ORCID: https://orcid.org/0000-0003-3138-0360)
- Gaku Moriyama
- Yumiko Ogawa‐Kobayashi
- Hiroyuki Kyoyama
- Shigeru Ishii (ORCID: https://orcid.org/0000-0001-9606-1083)
- Kazutsugu Uematsu (ORCID: https://orcid.org/0000-0003-0014-295X)
- Yusuke Hirata (ORCID: https://orcid.org/0000-0002-1428-2075)
- Shin Yokosuka
- Tomoyuki Takahashi (ORCID: https://orcid.org/0000-0002-8771-7666)
- Satoshi Kikuchi (ORCID: https://orcid.org/0000-0001-5099-5737)
- Hiroaki Nishimura (ORCID: https://orcid.org/0000-0003-2629-0942)
- Yuichiro Kawano
Institutions
- Social Insurance Saitama Chuo Hospital (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/cam4.71136
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00